drugset / Trial / NCT03143855
Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder
Phase 1
Completed
32 enrolled
Virginia Commonwealth University
National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The overall goal of this project is to develop initial human data on effects of novel compounds on safety (interactions with oxycodone) and efficacy (subjective response to oxycodone) in non-treatment seeking opioid use disorder subjects. The compound to be studied will be the 5-HT2CR agonist lorcaserin. There are no known or reported adverse interactions between lorcaserin and oxycodone or other opioids.
Timeline
- Start
- 2017-01-30
- Primary completion
- 2019-04-05
- Completion
- 2019-04-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lorcaserin | Small molecule | 10 mg | — |